An application of the 2-nitrobenzenesulfenyl method to proteomic profiling of human colorectal carcinoma: A novel approach for biomarker discovery

Proteomics - Clinical Applications

Volumn 2, Issue 6, 2008, Pages 925-935

  Watanabe, Makoto ^a,b   Takemasa, Ichiro ^a   Kawaguchi, Naomasa ^a   Miyake, Masakazu ^a   Nishimura, Noriko ^a,b   Matsubara, Toshiya ^a,b   Matsuo, Ei Ichi ^b   Sekimoto, Mitsugu ^a   Nagai, Katsuya ^a   Matsuura, Nariaki ^a   Monden, Morito ^a   Nishimura, Osamu ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b SHIMADZU CORPORATION   (Japan)

Author keywords

Biomarkers; Cancer; Colorectal carcinoma; NBS method

Indexed keywords

2 NITROBENZENESULFENYL; ALPHA TUBULIN; BETA TUBULIN; BIOLOGICAL MARKER; CHAPERONIN; CHAPERONIN 1; COMPLEMENT FACTOR H; CYTOKERATIN 18; ENOLASE; ENOLASE 1; EZRIN; F BOX PROTEIN; F BOX PROTEIN 40; FIBRINOGEN; FIBRINOGEN GAMMA; GALECTIN 1; GLUTATHIONE PEROXIDASE 1; GLYCINE TRANSFER RNA LIGASE; HEAT SHOCK PROTEIN 27; HLA C ANTIGEN; PLECTIN; PLECTIN 1; PROTEIN S18; PROTEIN S29; PYRUVATE KINASE; PYRUVATE KINASE 8; RADIXIN; REAGENT; RIBOSOME PROTEIN;

ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING;

EID: 46749104698     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780111     Document Type: Article

References (34)

1. Carpelan-Holmstrom, M. A., Haglund, C. H., Roberts, P. J., Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen. Dis. Colon Rectum. 1996, 39, 799-805.
2. Von Kleist, S., Hesse, Y., Kananeeh, H., Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res. 1996, 16, 2325-2332.
3. Carpelan-Holmstrom, M. A., Haglund, C. H., Javinen, H. J., Roberts, P. J. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Anticancer Res. 1996, 16, 981-986.
4. Takemasa, I., Higuchi, H., Yamamoto, H., Sekimoto. M. et al., Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem. Biophys. Res. Commun. 2001, 285, 1244-1249.
5. Komori, T., Takemasa, I., Higuchi, H., Yamasaki, M. et al., Identification of differentially expressed genes involved in colorectal carcinogenesis using a cDNA microarray. J. Exp. Clin. Cancer Res. 2004, 23, 521-527.
6. Tomonaga, T., Matsushita, K., Yamaguchi, S., Oh-Ishi, M. et al., Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res. 2004, 10, 2007-2014.
7. Roessler, M., Rollinger, W., Palme, S., Hagmann, M. et al., Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 2005, 11, 6550-6557.
8. Friedman, D. B., Hill, S., Keller, J. W., Merchant, N. B. et al., Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4, 793-811.
9. Stulik, J., Hernychova, L., Porkertova, S., Knizek, J. et al., Proteome study of colorectal carcinogenesis. Electrophoresis 2001, 22, 3019-3025.
10. Bi, X., Lin, Q., Foo, T. W., Joshi, S. et al., Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways. Mol. Cell. Proteomics 2006, 5, 1119-1130.
11. Rabilloud, T., Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains, Proteomics 2002, 2, 3-10.
12. Kuyama, H., Watanabe, M., Toda. C., Ando, E. et al., An approach to quantitative proteome analysis by labeling tryptophan residues. Rapid Commun. Mass Spectrom. 2003, 17, 1642-1650.
13. Matsuo, E., Toda, C., Watanabe, M., Iida, T. et al., Improved 2-nitrobenzenesulfenyl method: optimization of the protocol and improved enrichment for labeled peptides. Rapid Commun. Mass Spectrom. 2006, 20, 31-38.
14. Matsuo, E., Toda, C., Watanabe, M., Ojima, N. et al., Selective detection of 2-nitrobenzenesulfenyl-labeled peptides by matrix-assisted laser desorption/ionization-time of flight mass spectrometry using a novel matrix. Proteomics 2006, 6, 2042-2049.
15. Cagney, G., Amiri, S., Premawaradena, T., Lindo, M. et al., In silico proteome analysis to facilitate proteomics experiments using mass spectrometry. Proteome Sci. 2003, 13, 5.
16. Iida, T., Kuyama, H., Watanabe, M., Toda, C. et al., Rapid and efficient MALDI-TOF MS peak detection of 2-nitrobenzenesulfenyl labeled peptides using the combination of HPLC and an automatic spotting apparatus. J. Biomol. Tech. 2006, 17, 333-341.
17. Ou, K., Kesuma, D., Ganesan, K., Yu, K. et al., Quantitative profiling of drug-associated proteomic alterations by combined 2-nitrobenzenesulfenyl chloride (NBS) isotope labeling and 2DE/MS identification. J. Proteome Res. 2006, 5, 2194-2206.
18. Ueda, K., Katagiri, T., Shimada, T., Irie, S. et al., Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: A new approach for the novel biomarker discovery for cancer. J. Proteome Res. 2007, 6, 3475-3483.
19. Naghibalhossaini, F., Ebadi, P., Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett. 2006, 234, 158-167.
20. Macalma, T., Otte, J., Hensler, M. E., Bockholt, S. M. et al., Molecular characterization of human zyxin. J. Biol. Chem. 1996, 271, 31470-31478.
21. Sy, S. M., Lai, P. B., Pang, E., Wang, N. L. et al., Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma. Modern Pathol. 2006, 19, 1108-1116.
22. Ren, M., Drivas, G., D'Eustachio, P., Rush, M. G. Ran/TC4: a small nuclear GTP-binding protein that regulates DNA synthesis. J. Cell Biol. 1993, 120, 313-323.
23. Di Fiore, B., Ciciarello, M., Lavia, P. Mitotic functions of the Ran GTPase network: the importance of being in the right place at the right time. Cell Cycle 2004, 3, 305-313.
24. Ouellet, V., Guyot, M. C., Le Page, C., Filali-Mouhim, A. et al., Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 2006, 119, 599-607.
25. (2+)-binding protein with multiple EF-hand motifs. J. Biochem. 1997, 121, 145-149.
26. Liu, Z., Brattain, M. G., Appert, H. Differential display of Reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line. MCF-7. Biochem. Biophys. Res. Commun. 1997, 231, 283-289.
27. Vermeulen, S. J., Bruyneel, E. A., Bracke, M. E., De Bruyne, G. K. et al., Transition from the non-invasive to the invasive phenotype and loss of α-catenin in human colon cancer cells. Cancer Res. 1995, 55, 4122-4728.
28. Yu, L.R., Zeng, R., Shao, X.X., Wang, N. et al., Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimentional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis 2000, 21, 3058-3068.
29. de la Haba, G., Cantoni, G. L. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J. Biol. Chem. 1959, 234, 603-608.
30. Perillo, N. L., Marcus, M. E., Baum, L. G., Galectins:versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 1998, 76, 402-412.
31. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A. et al., A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 2005, 4, 1920-1932.
32. Ivaska, J., Pallari, H. M., Nevo, F. J., Eriksson, J. E., Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 2007, 313, 2050-2062.
33. Mori, D., Satoh, T., Nakafusa, F., Tanaka, M. et al., Primary colonic malignant melanoma. Pathol. Int. 2006, 56, 744-748.
34. Pavilidis, N., Cancer of unknown primary: biological and clinical characteristics. Ann. Oncology, 2003, 14, 11-18.